Poxel (0RA2) Stock Overview
A clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
0RA2 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Poxel S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.27 |
| 52 Week High | €0.83 |
| 52 Week Low | €0.22 |
| Beta | 1.54 |
| 1 Month Change | 9.24% |
| 3 Month Change | 14.05% |
| 1 Year Change | -30.61% |
| 3 Year Change | -60.47% |
| 5 Year Change | -95.81% |
| Change since IPO | -96.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RA2 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 7.3% | 4.8% | 1.2% |
| 1Y | -30.6% | 41.8% | 28.9% |
Return vs Industry: 0RA2 underperformed the UK Biotechs industry which returned 41.8% over the past year.
Return vs Market: 0RA2 underperformed the UK Market which returned 28.9% over the past year.
Price Volatility
| 0RA2 volatility | |
|---|---|
| 0RA2 Average Weekly Movement | 28.6% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 12.0% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: 0RA2's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RA2's weekly volatility has increased from 20% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 5 | Nicolas Trouche | www.poxelpharma.com |
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan.
Poxel S.A. Fundamentals Summary
| 0RA2 fundamental statistics | |
|---|---|
| Market cap | €14.64m |
| Earnings (TTM) | -€13.66m |
| Revenue (TTM) | €7.66m |
Is 0RA2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RA2 income statement (TTM) | |
|---|---|
| Revenue | €7.66m |
| Cost of Revenue | €3.67m |
| Gross Profit | €3.98m |
| Other Expenses | €17.65m |
| Earnings | -€13.66m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 52.02% |
| Net Profit Margin | -178.45% |
| Debt/Equity Ratio | -101.0% |
How did 0RA2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/20 00:54 |
| End of Day Share Price | 2026/04/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Poxel S.A. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Butler | Citizens JMP Securities, LLC |
| David Seynnaeve | Degroof Petercam |
| Peter Welford | Jefferies LLC |